The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...
Hosted on MSN2mon
Drug Ads Misinform Patients and Raise Health Care CostsAbbVie is also the largest drug ad spender across the pharmaceutical industry, shelling out almost $580 million on Skyrizi alone in 2023. Such profits come with unnecessary drug prescriptions ...
Ads during women's sports programs were 40% more impactful than the average primetime advertisement, according to EDO.
AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...
New data with AbbVie’s IL-23 inhibitor Skyrizi suggests it can alleviate symptoms in psoriasis patients who don’t respond well to other biologics for the skin disease, including widely-used IL ...
Skyrizi (risankizumab-rzaa) is prescribed for Crohn’s disease and certain other inflammatory conditions. As with other drugs, Skyrizi can cause side effects, such as headache and injection site ...
Pharma brands achieved the most impressions from ABC and saw a year-over-year increase in impressions from cable channels like Fox News, CNN and MSNBC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback